These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30198775)

  • 1. Feasibility of Intravenous Iron Isomaltoside to Improve Anemia and Quality of Life During Palliative Chemotherapy for Esophagogastric Adenocarcinoma.
    Ng O; Keeler B; Simpson JA; Madhusudan S; Brookes M; Acheson A
    Nutr Cancer; 2018 Oct; 70(7):1106-1117. PubMed ID: 30198775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
    Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
    Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer.
    Keeler BD; Simpson JA; Ng S; Tselepis C; Iqbal T; Brookes MJ; Acheson AG
    Colorectal Dis; 2014 Oct; 16(10):794-800. PubMed ID: 24916374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
    Abbrederis K; Bassermann F; Schuhmacher C; Voelter V; Busch R; Roethling N; Sendler A; Siewert JR; Peschel C; Lordick F
    Ann Thorac Surg; 2006 Jul; 82(1):293-7. PubMed ID: 16798232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating Anemia in the Preanesthesia Assessment Clinic: Results of a Retrospective Evaluation.
    Ellermann I; Bueckmann A; Eveslage M; Buddendick H; Latal T; Niehoff D; Geissler RG; Hempel G; Kerkhoff A; Berdel WE; Roeder N; Van Aken HK; Zarbock A; Steinbicker AU
    Anesth Analg; 2018 Nov; 127(5):1202-1210. PubMed ID: 29944518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
    Gybel-Brask M; Seeberg J; Thomsen LL; Johansson PI
    Transfusion; 2018 Apr; 58(4):974-981. PubMed ID: 29424441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
    Dahlerup JF; Jacobsen BA; van der Woude J; Bark LÅ; Thomsen LL; Lindgren S
    Scand J Gastroenterol; 2016 Nov; 51(11):1332-8. PubMed ID: 27326766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
    Stein J; Walper A; Klemm W; Farrag K; Aksan A; Dignass A
    Scand J Gastroenterol; 2018 Sep; 53(9):1059-1065. PubMed ID: 30222479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
    Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
    Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer.
    Park SH; Nam E; Bang SM; Cho EK; Shin DB; Lee JH
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):1-9. PubMed ID: 17690882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of high-dose intravenous iron as the first-choice therapy in outpatients with severe iron deficiency anemia.
    Jericó C; Beverina I; Quintana-Diaz M; Salvadori U; Melli C; Rondinelli MB; Recasens V; Brando B; Garcia-Erce JA
    Transfusion; 2020 Jul; 60(7):1443-1449. PubMed ID: 32597514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
    Derman R; Roman E; Modiano MR; Achebe MM; Thomsen LL; Auerbach M
    Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single dose of intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of postoperative anaemia in colorectal cancer patients: study protocol for a randomised controlled trial.
    Laso-Morales MJ; Vives R; Vallejo-Tarrat A; Caló N; Valle-Beltran A; Pontes C
    Trials; 2019 Jan; 20(1):23. PubMed ID: 30616657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study.
    Holm C; Thomsen LL; Norgaard A; Langhoff-Roos J
    Vox Sang; 2017 Feb; 112(2):122-131. PubMed ID: 28010050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease.
    Reinisch W; Altorjay I; Zsigmond F; Primas C; Vogelsang H; Novacek G; Reinisch S; Thomsen LL
    Scand J Gastroenterol; 2015; 50(10):1226-33. PubMed ID: 25900645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.